← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb

Traditional approvalTraditional conversionColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As subcutaneous monotherapy for adults with metastatic MSI-high or mismatch repair-deficient colorectal cancer after progression following fluoropyrimidine, oxaliplatin, and irinotecan.

LAMPGEN ANALYSIS

Why it matters

The supplement fulfilled postmarketing requirements and converted the existing subcutaneous post-chemotherapy use to traditional approval.

What research teams should watch

Keep this post-chemotherapy pathway distinct from the same-day use after intravenous dual immunotherapy.

PRIMARY RECORDS

Sources